GlassScriptPhysician profile
Bhupat A Desai
NPI 1649362633
$6,061.52
in general payments reported to CMS, 2019-2025
32 companies · $1,244 in 2025
The $1,244 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $273 · 2020: $135 · 2021: $250 · 2022: $1,008 · 2023: $1,248 · 2024: $1,904 · 2025: $1,244.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,396.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,395.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,039.03 | 2021-2025 | Botox, Ubrelvy, Qulipta |
| Acadia Pharmaceuticals INC | $1,069.66 | 2019-2025 | Nuplazid |
| Medtronic, INC. | $763.37 | 2021-2023 | Activa PC |
| Novartis Pharmaceuticals Corporation | $385.62 | 2020-2024 | |
| Biogen, INC. | $222.73 | 2019-2025 | Tysabri |
| Allergan, INC. | $199.02 | 2019-2022 | |
| Eisai INC. | $196.13 | 2024-2025 | |
| Alexion Pharmaceuticals, INC. | $159.84 | 2023-2024 | Ultomiris |
| Emd Serono, INC. | $121.54 | 2019-2025 | |
| Pfizer INC. | $109.01 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $105.84 | 2019 | |
| Celgene Corporation | $93.63 | 2023-2024 | Zeposia |
| Livanova USA, INC. | $84.02 | 2021 | |
| Abbott Laboratories | $67.02 | 2021 | |
| Octapharma USA, INC. | $51.49 | 2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mdd US Operations, LLC | $51.38 | 2023-2025 | Apokyn |
| Penumbra, INC. | $37.81 | 2020 | |
| Lundbeck LLC | $36.25 | 2023-2024 | Rexulti |
| Argenx US, INC. | $34.49 | 2023 | Vyvgart Hytrulo |
| Amgen INC. | $32.33 | 2024 | Uplizna |
| Teva Pharmaceuticals USA, INC. | $23.48 | 2021 | |
| Adamas Pharmaceuticals, INC. | $22.97 | 2020 | |
| Amneal Pharmaceuticals LLC | $21.84 | 2024 | Rytary |
| Azurity Pharmaceuticals, INC. | $20.17 | 2025 | |
| Genentech USA, INC. | $19.64 | 2022 | |
| Sunovion Pharmaceuticals INC. | $17.35 | 2022 | |
| Ucb, INC. | $17.06 | 2025 | Nayzilam |
| Otsuka America Pharmaceutical, INC. | $15.55 | 2023 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $15.55 | 2024 | Hyqvia |
| Boston Scientific Corporation | $15.10 | 2021 | |
| Zogenix INC. | $12.60 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bhupat Desai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.